<?xml version="1.0" encoding="UTF-8"?>
<article version="1.0" id="614432ddc9975a445d4d6ae4">
  <languages>
    <lang>en_GB</lang>
    <lang>zh_CN</lang>
    <lang>zh_TW</lang>
  </languages>
  <pubdate>2021-09-21T07:49:43+00:00</pubdate>
  <ads_disabled>false</ads_disabled>
  <headline>
    <title lang="en_GB">A new AIDS vaccine heads to clinical trials</title>
    <title lang="zh_CN">一种新型艾滋病疫苗进入临床试验</title>
    <title lang="zh_TW">一種新型艾滋病疫苗進入臨床試驗</title>
    <fly_title lang="en_GB">The other pandemic</fly_title>
    <fly_title lang="zh_CN">另一种大流行病</fly_title>
    <fly_title lang="zh_TW">另一種大流行病</fly_title>
    <section lang="en_GB">Science &amp; technology</section>
    <section lang="zh_CN">​</section>
    <section lang="zh_TW">​</section>
  </headline>
  <body>
    <rubric lang="en_GB">It uses the same mRNA technology as some covid jabs</rubric>
    <rubric lang="zh_CN">它所用的mRNA技术与某些新冠疫苗相同</rubric>
    <rubric lang="zh_TW">它所用的mRNA技術與某些新冠疫苗相同</rubric>
    <content>
      <image>
        <url lang="en_GB">images/614432ddc9975a445d4d6ae4_en_GB_0_quipimage.jpeg</url>
        <url lang="zh_CN">images/614432ddc9975a445d4d6ae4_zh_CN_0_quipimage.jpeg</url>
        <url lang="zh_TW">images/614432ddc9975a445d4d6ae4_zh_CN_0_quipimage.jpeg</url>
        <caption lang="en_GB"/>
        <caption lang="zh_CN">​</caption>
        <caption lang="zh_TW">​</caption>
      </image>
      <paragraph>
        <copy lang="en_GB">ONE SILVER lining to the covid-19 pandemic has been the speed with which effective vaccines have been developed. Victims of other pandemics have not been so lucky. Three decades of attempts to create a vaccine against HIV, the virus that causes AIDS, have proved fruitless. The latest setback came on August 31st, when an experimental vaccine produced by Johnson &amp; Johnson, an American pharmaceutical firm, flunked a clinical trial. One obstacle is HIV’s genetic slipperiness. The virus has a high mutation rate, which helps it adapt to evade both natural immune systems and artificial vaccines.</copy>
        <copy lang="zh_CN">新冠疫情乌云中的一道曙光是有效疫苗的快速研发。其他大流行病的患者就没这么幸运了。30年来，研究人员一直在研制疫苗以求对抗导致艾滋病的HIV病毒，但始终徒劳无功。最近一次挫败发生在8月31日，美国制药公司强生研制的一种试验性疫苗未能通过临床试验。一个难点是HIV的基因很不稳定。这种病毒具有很高的突变率，有助于它适应新情况以逃避自然免疫系统和人工疫苗的攻击。</copy>
        <copy lang="zh_TW">新冠疫情烏雲中的一道曙光是有效疫苗的快速研發。其他大流行病的患者就沒這麼幸運了。30年來，研究人員一直在研製疫苗以求對抗導致艾滋病的HIV病毒，但始終徒勞無功。最近一次挫敗發生在8月31日，美國製藥公司強生研製的一種試驗性疫苗未能通過臨床試驗。一個難點是HIV的基因很不穩定。這種病毒具有很高的突變率，有助於它適應新情況以逃避自然免疫系統和人工疫苗的攻擊。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Undaunted, Moderna, a firm based in Massachusetts that has recently found fame by quickly coming up with a viable covid-19 jab, is planning to start human trials of a novel vaccine against HIV. Its researchers hope that the mRNA technology used to produce its covid-19 jab will succeed against HIV too, by creating a vaccine which the virus cannot easily dodge.</copy>
        <copy lang="zh_CN">总部位于马萨诸塞州的莫德纳（Moderna）公司不为所惧，正计划启动一种新型HIV疫苗的人体试验。这家公司近来因为迅速推出了有效的新冠疫苗而声名鹊起。它的研究人员希望它用于生产新冠疫苗的mRNA技术也能成功创造出一种让HIV病毒无法轻易逃逸的疫苗。</copy>
        <copy lang="zh_TW">總部位於馬薩諸塞州的莫德納（Moderna）公司不為所懼，正計劃啟動一種新型HIV疫苗的人體試驗。這家公司近來因為迅速推出了有效的新冠疫苗而聲名鵲起。它的研究人員希望它用於生產新冠疫苗的mRNA技術也能成功創造出一種讓HIV病毒無法輕易逃逸的疫苗。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Moderna’s approach is based in part on work by the International AIDS Vaccine Initiative (IAVI), a charity, and Scripps Research, a not-for-profit institute in San Diego. A joint study published in February showed, for the first time in humans, that it is possible to stimulate activity in immune cells called germline B-cells, which can produce things called broadly neutralising antibodies (bnAbs) against HIV.</copy>
        <copy lang="zh_CN">在一定程度上，莫德纳的方法是基于慈善机构国际艾滋病疫苗倡议组织（以下简称IAVI）和圣迭戈的非营利机构Scripps Research的研究。这两者在2月发表的一项联合研究首次发现，有可能在人体中激发被称为生殖系B细胞的免疫细胞的活性，这种细胞可以产生对抗HIV病毒的广泛中和抗体（bnAbs）。</copy>
        <copy lang="zh_TW">在一定程度上，莫德納的方法是基於慈善機構國際艾滋病疫苗倡議組織（以下簡稱IAVI）和聖迭戈的非營利機構Scripps Research的研究。這兩者在2月發表的一項聯合研究首次發現，有可能在人體中激發被稱為生殖系B細胞的免疫細胞的活性，這種細胞可以產生對抗HIV病毒的廣泛中和抗體（bnAbs）。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Antibodies are proteins produced by the immune system in response to infection. Through a process of quick-fire trial and error in response to particular pathogen molecules, known as antigens, the body creates specialised molecules designed either to gum up the workings of pathogens, or to flag them for destruction by other parts of the immune system. But most antibodies turned out in response to HIV fail to stem the infection for the same reason vaccines do—the virus’s rapid mutation rate allows it to evolve to avoid them.</copy>
        <copy lang="zh_CN">抗体是免疫系统应对感染而产生的蛋白质。通过抵抗被称为抗原的特定病原体分子的快速试错过程，身体会产生专门的分子来破坏病原体的运作，或将病原体标记出来，由免疫系统的其他部分加以破坏。但人体内大多数对付HIV病毒的抗体无法阻止感染，因为这种病毒的高突变率让它能够不断进化以逃逸抗体，疫苗不起作用的原因也在于此。</copy>
        <copy lang="zh_TW">抗體是免疫系統應對感染而產生的蛋白質。通過抵抗被稱為抗原的特定病原體分子的快速試錯過程，身體會產生專門的分子來破壞病原體的運作，或將病原體標記出來，由免疫系統的其他部分加以破壞。但人體內大多數對付HIV病毒的抗體無法阻止感染，因為這種病毒的高突變率讓它能夠不斷進化以逃逸抗體，疫苗不起作用的原因也在於此。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">As their name suggests, bnAbs are less susceptible to such countermeasures. In the case of HIV, the antigen they recognise is part of a viral protein called gp120. This is the means by which HIV particles “dock” with their target cells prior to infecting them. The part of the protein that does the docking is so well tailored that almost any mutation will make it less effective. Since gp120 is trapped in an evolutionary corner, it is a desirable target for a vaccine.</copy>
        <copy lang="zh_CN">从广泛中和抗体的名字上可以看出，它们不太容易受这种逃逸机制的影响。在遭遇HIV病毒时，它们所识别出的抗原是病毒蛋白gp120的一部分。HIV病毒颗粒在感染目标细胞之前通过这种蛋白与目标细胞“结合”。gp120上负责结合的那一部分非常严丝合缝，几乎任何突变都会降低其功效。因此gp120陷入了进化的死角，是疫苗的理想靶标。</copy>
        <copy lang="zh_TW">從廣泛中和抗體的名字上可以看出，它們不太容易受這種逃逸機制的影響。在遭遇HIV病毒時，它們所識別出的抗原是病毒蛋白gp120的一部分。HIV病毒顆粒在感染目標細胞之前通過這種蛋白與目標細胞“結合”。gp120上負責結合的那一部分非常嚴絲合縫，幾乎任何突變都會降低其功效。因此gp120陷入了進化的死角，是疫苗的理想靶標。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Germline B-cells are diverse but rare. Each carries the blueprint of an antibody, and stands ready to do two things when alerted to the presence of a pathogen. The first is a process called somatic hypermutation, which generates daughter cells capable of producing many slightly different versions of that antibody. The second is clonal expansion, in which cells carrying the most successful of these variants multiply to deal with the infection.</copy>
        <copy lang="zh_CN">生殖系B细胞种类繁多但数量很少。它们每个都携带着一个特定抗体的图谱，并准备好在发现有病原体时做两件事。第一是体细胞超突变，在此过程中一个生殖系B细胞会生成子细胞，这些子细胞能产生其携带抗体的众多略有不同的版本。二是克隆扩增，在这个过程中，携带最有效的那版抗体的细胞会自我复制以对抗感染。</copy>
        <copy lang="zh_TW">生殖系B細胞種類繁多但數量很少。它們每個都攜帶着一個特定抗體的圖譜，並準備好在發現有病原體時做兩件事。第一是體細胞超突變，在此過程中一個生殖系B細胞會生成子細胞，這些子細胞能產生其攜帶抗體的眾多略有不同的版本。二是克隆擴增，在這個過程中，攜帶最有效的那版抗體的細胞會自我複製以對抗感染。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">The study conducted by IAVI and Scripps used a small engineered protein called eOD-GT8 60mer as an antigen. This protein resembles the cell-docking part of gp120. Crucially, empirical work in both mice and humans has shown that it also stimulates somatic hypermutation in germline B-cells carrying a broadly neutralising antibody called VRC01. That makes it a promising basis for a vaccine.</copy>
        <copy lang="zh_CN">IAVI和Scripps的研究把一种名为eOD-GT8 60mer的小型基因工程蛋白用作抗原。这种蛋白质类似于gp120上与细胞结合的那一部分。至关重要的是，对小鼠和人体的实证研究表明，它也刺激了携带名为VRC01的广泛中和抗体的B细胞的体细胞超突变过程。这让它有望成为一种有效疫苗的基础。</copy>
        <copy lang="zh_TW">IAVI和Scripps的研究把一種名為eOD-GT8 60mer的小型基因工程蛋白用作抗原。這種蛋白質類似於gp120上與細胞結合的那一部分。至關重要的是，對小鼠和人體的實證研究表明，它也刺激了攜帶名為VRC01的廣泛中和抗體的B細胞的體細胞超突變過程。這讓它有望成為一種有效疫苗的基礎。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">The problem with this approach is that eOD-GT8 60mer is slow and expensive to make. Which is where Moderna’s technology comes in. mRNA is the messenger molecule that carries, from a cell’s chromosomes, instructions which tell that cell how to make particular proteins. Instead of carrying eOD-GT8 60mer itself, Moderna’s vaccine contains the mRNA instructions on how to make it, and leaves the job of production to the body’s own cells. Once the molecule enters the bloodstream, it should stimulate the VRC01-carrying germline B-cells to do their stuff. After that, booster shots employing mRNAs for other small antigenic proteins will be used to guide the process of hypermutation in the right direction.</copy>
        <copy lang="zh_CN">这种方法的问题是制备eOD-GT8 60mer的过程很慢且成本很高。莫德纳的技术在此有了用武之地。mRNA是一种信使分子，它携带来自细胞染色体的指令，告诉细胞如何制造特定的蛋白质。莫德纳的疫苗本身并不含有eOD-GT8 60mer，而是携带如何制造它的mRNA指令，把生产这种蛋白的工作留给人体自身的细胞。一旦mRNA进入血液，它应该就会刺激携带VRC01的生殖系B细胞发挥作用。之后，指示生成其他小抗原蛋白的mRNA疫苗加强针会指导超突变过程朝着正确的方向推进。</copy>
        <copy lang="zh_TW">這種方法的問題是製備eOD-GT8 60mer的過程很慢且成本很高。莫德納的技術在此有了用武之地。mRNA是一種信使分子，它攜帶來自細胞染色體的指令，告訴細胞如何製造特定的蛋白質。莫德納的疫苗本身並不含有eOD-GT8 60mer，而是攜帶如何製造它的mRNA指令，把生產這種蛋白的工作留給人體自身的細胞。一旦mRNA進入血液，它應該就會刺激攜帶VRC01的生殖系B細胞發揮作用。之後，指示生成其他小抗原蛋白的mRNA疫苗加強針會指導超突變過程朝着正確的方向推進。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">The trial is an early one, designed to test safety and prove the principle. It is testing two approaches. One uses only the mRNA for eOD-GT8 60mer. The other adds mRNA for one of the small, guiding antigens to the shot. It will begin in America later this month, with 56 people. Trials in Rwanda and South Africa should follow shortly after. (UNAIDS, the body charged by the United Nations with combating HIV, estimates that two-thirds of the 38m people infected with the virus by the end of 2020 were in Africa.)</copy>
        <copy lang="zh_CN">该项试验还处于早期阶段，目标是测试安全性并验证原理。它正在测试两种方法。一种仅使用mRNA来生成eOD-GT8 60mer。另一种在疫苗中添加mRNA以生成一种小引导抗原。试验将于本月晚些时候在美国开始，有56人参加。不久之后还将在卢旺达和南非展开试验。（联合国负责抗击艾滋病的机构联合国艾滋病规划署[UNAIDS]估计，到2020年底，全球3800万艾滋病病毒感染者中有三分之二在非洲。）</copy>
        <copy lang="zh_TW">該項試驗還處於早期階段，目標是測試安全性並驗證原理。它正在測試兩種方法。一種僅使用mRNA來生成eOD-GT8 60mer。另一種在疫苗中添加mRNA以生成一種小引導抗原。試驗將於本月晚些時候在美國開始，有56人參加。不久之後還將在盧旺達和南非展開試驗。（聯合國負責抗擊艾滋病的機構聯合國艾滋病規劃署[UNAIDS]估計，到2020年底，全球3800萬艾滋病病毒感染者中有三分之二在非洲。）</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">The results from the American trial are expected in 2023. Beyond that, the timeline is less clear. Mark Feinberg, IAVI’s boss, citing how difficult HIV vaccine development still is, does not want people thinking that “just because the covid vaccines were developed using RNA technology in less than a year we’re going to have an HIV vaccine in less than a year”. After three decades of waiting, though, a little more patience is not too much to ask. ■</copy>
        <copy lang="zh_CN">在美国的试验预计将于2023年得出结果。再往后的时间表就不太明确了。IAVI的总裁马克·范伯格（Mark Feinberg）提到HIV疫苗的研发仍然困难重重，他不希望人们会以为“仅仅因为不到一年时间就用RNA技术开发出了新冠疫苗，我们就能在不到一年的时间内获得HIV疫苗”。不过反正都已经等了30年，再多给一点点耐心也不是什么太过分的要求。</copy>
        <copy lang="zh_TW">在美國的試驗預計將於2023年得出結果。再往後的時間表就不太明確了。IAVI的總裁馬克·范伯格（Mark Feinberg）提到HIV疫苗的研發仍然困難重重，他不希望人們會以為“僅僅因為不到一年時間就用RNA技術開發出了新冠疫苗，我們就能在不到一年的時間內獲得HIV疫苗”。不過反正都已經等了30年，再多給一點點耐心也不是什麼太過分的要求。</copy>
      </paragraph>
    </content>
    <idioms/>
  </body>
</article>
